20 Dec 2013 07:00

Â
Omega Diagnostics Group PLC
("Omega" or the "Company")
Â
CD4 Update
Â
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.
Â
As reported last month with the interim results, we selected a preferred manufacturing protocol to proceed to a three-batch validation. The Company is pleased to announce that it has produced a first reference batch which, when tested on patient samples, has produced results which are within the agreed design specification for the accuracy of the test and which demonstrate a significant reduction in the levels of variability previously reported.
Â
This is an important milestone in the technology transfer project and we will proceed to test the protocol with further independent manufacturing runs.
Â
The Board has increased confidence in successfully completing the three-batch validation and, given the proximity to Christmas, we will provide a further update early in the New Year.
Â
Â
Â
Contacts:
Â
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul Cornelius | Mob: 07866 384 707 |
Lianne Cawthorne | Mob: 07584 391 303 |
Â